CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
Sugammadex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02484651
NCT02484651Phase 4Completed

Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade: a Randomized Controlled Study Assessing Propofol and Remifentanil Requirements and Quality of Recovery in Patients With a Standard Practice of Non-deep Rocuronium Neuromuscular Blockade Versus Deep Neuromuscular Blockade Reversed With Sugammadex

Centro Hospitalar do Porto·interventional·Posted Jun 29, 2015·Updated Sep 16, 2019

In Brief

A Phase 4 clinical trial evaluating Sugammadex and Rocuronium for Neuromuscular Block. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The investigators hypothesize that an anesthetic protocol maintaining deep neuromuscular block throughout the entire surgical procedure followed by sugammadex reversal, would suppress EMG activity and result in improved anesthetic stability by reducing the variability of the Bispectral Index of the EEG, and be beneficial by reducing the total doses of the anesthetic drugs propofol and remifentanil required to maintain an adequate level of anesthesia (BIS between 40 and 60).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPortugal

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 29, 2015
Enrollment StartSep 1, 2016
Primary CompletionJun 28, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.0 years ago

Interventions

Sugammadexdrug

Reversal of deep neuromuscular block

Rocuroniumdrug

Maintenance of deep neuromuscular block